Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12766236 | 1.00 | LMNA (0.40) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL7606793 | 1.00 | LMNA (0.40) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL13213433 | 0.89 | FOLH1 (0.46) | LMNACYP2C9RNPEPFOLH1ALDH1A1 | |
| SCHEMBL19729236 | 0.86 | LMNA (0.41) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL17431202 | 0.86 | LMNA (0.41) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL24172616 | 0.85 | RNPEP (0.36) | LMNACYP2C9RNPEP | |
| SCHEMBL19386700 | 0.84 | CYP2C9 (0.36) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL21216215 | 0.83 | METAP2 (0.33) | — | |
| SCHEMBL21677992 | 0.82 | RNPEP (0.39) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL21677920 | 0.82 | RNPEP (0.39) | LMNACYP2C9RNPEPTSHRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20220143038-A1 | LIPID PRODRUGS OF MYCOPHENOLIC ACID AND USES THEREOF | PURETECH LYT, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | LMNA 2962/4885CYP2C9 276/4885RNPEP 2712/4885 |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | LMNA 4263/4885CYP2C9 320/4885RNPEP 2049/4885 |
| US-20220143038-A1 | LIPID PRODRUGS OF MYCOPHENOLIC ACID AND USES THEREOF | MALT1, CYP2B6, LIPA | LMNA 4002/4885CYP2C9 51/4885RNPEP 870/4885 |
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | LIPA, MALT1, SGMS1 | LMNA 2779/4885CYP2C9 312/4885RNPEP 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.